New chemo combo shows promise for rare sarcoma

NCT ID NCT04605770

Recruiting now Disease control Sponsor: Yonsei University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial is testing the combination of two chemotherapy drugs, pemetrexed and cisplatin, in 164 adults with advanced or recurrent soft tissue sarcoma. The goal is to see if this treatment can slow tumor growth in people who have already tried standard therapies. Participants will receive up to 6 cycles of the combination, followed by pemetrexed alone, and will be monitored for response and side effects.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pemetrexed and cisplatin (chemotherapy drugs)
What this could lead to: If successful, this could provide a new chemotherapy option for people with advanced soft tissue sarcoma who have not responded to standard treatments.
What could go wrong: This is an early-phase trial with a small number of participants. The drugs may not work better than existing options, and side effects from chemotherapy can be serious.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for SARCOMA,SOFT TISSUE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SARCOMA,SOFT TISSUE

Contacts and locations

Locations

Severance Hospital
RECRUITING

Seoul, 03722, South Korea

More trials for these conditions

Other studies related to the condition(s) this trial covers.